norharman has been researched along with aspirin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, X; Liu, J; Peng, L; Peng, S; Zhang, X; Zhao, M; Zheng, M | 1 |
| Li, C; Liu, J; Peng, S; Wang, Y; Wu, J; Zhang, X; Zhao, M; Zheng, M | 1 |
2 other study(ies) available for norharman and aspirin
| Article | Year |
|---|---|
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
Topics: Amino Acids; Animals; Carbolines; Fibrinolytic Agents; In Vitro Techniques; Male; Models, Molecular; Molecular Conformation; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Swine | 2010 |
A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
Topics: Animals; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Drug Design; Fibrinolytic Agents; Hydrazines; Male; Models, Molecular; Molecular Conformation; Platelet Aggregation; Platelet Aggregation Inhibitors; Quantitative Structure-Activity Relationship; Rats; Swine; Thrombosis | 2011 |